Table 3.
Baseline (Time 0) versus follow-up at 10 months (Time 2) comparison.
| N = 30 | Time 0 | Time 2 | p-value |
|---|---|---|---|
| % LTCD3* | 69.1 ± 7.7 | 69 ± 6.5 | 0.9676 |
| %LTCD4* | 44.6 ± 8.3 | 45.8 ± 7.4 | 0.0179 |
| % LT CD8** | 21 (18–24.9) | 20.1 (16.9–23.2) | 0.0002 |
| CD4 count ** | 1074 (860–1316) | 1217.5 (838–1510) | 0.0016 |
| CD8 count ** | 494 (355–634) | 502.5 (378–632) | 0.3876 |
| CD4/CD8 ratio ** | 2.2 (1.7–2.7) | 2.4 (1.8–2.8) | 0.0001 |
| % LB CD19* | 16.7 ± 6.1 | 16.5 ± 5.2 | 0.5881 |
| % LB CD20** | 15.9 (12.8–20) | 15.6 (12.8–19.1) | 0.2989 |
| CD19 count* | 416 ± 202.3 | 448.8 ± 187.3 | 0.1808 |
| CD20 ** | 404 (272–511) | 426 (293–588) | 0.2667 |
| C3* | 164 ± 40.6 | 112.4 ± 31.4 | <0.001 |
| C4* | 29.3 ± 10.1 | 22.5 ± 7.1 | 0.0009 |
| Leptin | 44.12 ± 9.75 | 22.49 ± 9.7 | <0.001 |
| Adiponectin* | 29.2 ± 20.17 | 40.8 ± 23.4 | 0.042 |
| Anticardiolipin IgG antibodies** | 7 (6–10.5) | 3 (2.6–5.2) | <0.001 |
| Anticardiolipin IgM antibodies ** | 0.95 (0.7–1.4) | 0.95 (0.8–1.4) | 0.4601 |
| Rheumatoid factor* | 5.5 ± 1.7 | 3.6 ± 1.7 | <0.001 |
*Mean ± SD, ** Median (IQR), *Paired t-test, ** Wilcoxon signed-rank test.